Archer Materials (ASX: AXE) reported meaningful technical progress across its quantum computing and medical diagnostics platforms during the December 2025 quarter.
The company said advances in quantum state readout for its carbon-based qubit materials further de-risk the 12CQ project and move it closer to qubit demonstration.
Archer also strengthened its commercial pathway through new collaborations with Emergence Quantum and CSIRO, extending its reach into next-generation quantum devices and quantum-enhanced machine learning.
In parallel, the Biochip program achieved a critical milestone after silicon-based devices met clinical blood potassium accuracy standards in collaboration with IMEC.
12CQ Quantum Technology Progress
Archer advanced readout technology for its carbon-based qubit material during the quarter, demonstrating that quantum spin states can be electrically detected directly on a chip.
The company also achieved electrical gating of its carbon films using electrically detected magnetic resonance, supporting control of charge and spin at the nanoscale.
Multiple design and fabrication cycles were completed to refine gating and single-electron transistor architectures critical to scalable qubit development.
Archer further strengthened platform scalability by synthesising its qubit material on a one-inch silicon wafer.
Electron spin lifetimes exceeding 0.4 microseconds were demonstrated at room temperature, comparing favourably with several established quantum computing platforms.
Strategic Collaborations
Archer signed a collaboration agreement with Emergence Quantum to identify graphene and carbon-based technologies for next-generation quantum and electronic devices.
The partnership is intended to broaden Archer’s technology exposure while accelerating pathways toward commercial quantum applications.
Separately, the company entered into a year-long agreement with CSIRO to develop quantum machine learning models focused on improving financial fraud detection.
Archer said hybrid quantum-classical models developed through the project may be extended to other high-value use cases over time.
“These partnerships are instrumental in bolstering our pathway to potential future commercialisation of the 12CQ quantum project," executive chair Greg English said.
Biochip Development Milestone
The Biochip program delivered a significant result after silicon-based devices demonstrated blood potassium measurement accuracy that met clinical standards.
Testing with IMEC showed the silicon devices matched the performance of Archer’s graphene-based devices while offering faster readout times.
Archer expects the transition to a silicon platform will de-risk supply chains, reduce manufacturing costs, and accelerate the pathway to regulatory approval.
The Biochip program is moving toward point-of-care potassium testing, particularly for patients with chronic kidney disease.
Corporate Appointment
During the quarter, Andrew Just was appointed as a non-executive director following the resignation of Ken Williams.
Archer said Mr Just brings extensive global experience in scaling health and medical technology businesses, strengthening the board as the Biochip program progresses.
At 31 December 2025, the company held cash of $10.3 million, excluding a $2.1m research and development tax rebate received in January.
Archer remains well-funded with no debt, as it continues to advance both its quantum computing and medical diagnostics platforms.
“Overall, these achievements highlight the strength of our technology platforms and partnerships as we continue to build a company that aims to commercialise quantum technology across computing, sensing, and medical diagnostics,” Mr English said.
